Cytokinetics, Inc.
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
17
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 15 to 24, 2027 · next Mar 15
- 2 fees due Jul 28 to 30, 2027 · next Jul 28
- 5 fees due Sep 5 to 19, 2027 · next Sep 5
- 3 fees due Oct 9 to 23, 2027 · next Oct 9
- 1 fee due Nov 14, 2027The maintenance fee for Bicyclic 1,4-Diazepanones and Therapeutic Uses Thereof (US 11,981,644) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,871,768 | Certain chemical entities, compositions and methods In force · From the USPTO record | In force | From the USPTO record | |
| US 7,825,120 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas In force · From the USPTO record | In force | From the USPTO record | |
| US 7,507,735 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 12,264,133 | Compounds, Compositions and Methods In force · High confidence | In force | High confidence | |
| US 7,598,248 | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use In force · From the USPTO record | In force | From the USPTO record | |
| US 7,956,056 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,766,899 | Methods for preparing substituted imidazo[4,5-b]pyrazines In force · From the USPTO record | In force | From the USPTO record | |
| US 8,110,595 | Ureas and Their Use in the Treatment of Heart Failure In force · Medium confidence | In force | Medium confidence | |
| US 7,718,657 | Certain indanyl urea modulators of the cardiac sarcomere In force · From the USPTO record | In force | From the USPTO record | |
| US 8,293,761 | Certain chemical entities, compositions and methods In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 69: 12 patents in force now held by others · 147 lapsed for an unpaid fee · 49 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
15 pending · 17 abandoned · 59 no status recorded